Pacira BioSciences, Inc. (PCRX)
Valuation Overview•Is Pacira BioSciences, Inc. Overvalued or Undervalued?
Trading at a relative discount to industry peers, suggesting a specific risk premium is applied.
Moderate quality score of 52/100, reflecting stable operating margins and manageable leverage.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Verdict: Average quality business weighed down by significant profitability concerns.
Wall Street is highly bullish, projecting significant upside alongside robust expected earnings growth. This outlook is strongly supported by highly attractive capital returns, driven predominantly by aggressive share repurchases.
Returns capital exclusively via buybacks — no active dividend
PCRX demonstrates adequate business quality with stable profitability. However, the balance sheet carries elevated leverage, requiring careful monitoring of debt servicing capabilities.
The company exhibits steady, low-single-digit revenue growth however, earnings have severely contracted over the same period. However, profitability remains a major concern with severely compressed operating margins (3.4%).
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $177.4M | +3.6% | +2.9% | +11.1% | +11.3% | |
| EBITDA | $6.9M | — | -6.4% | — | — | |
| Net Income | $7.1M | +107.1% | -23.8% | — | +14.3% | |
| EPS (Diluted) | $0.07 | +107.4% | -22.2% | -45.5% | +14.9% | |
| Free Cash Flow | $23.0M | -23.5% | +5.9% | +28.4% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 60.2% | 75.9% | 74.4% | 72.3% |
| Operating Margin | 3.4% | 2.4% | 6.5% | 3.0% |
| Net Margin | 1.3% | -2.3% | 0.6% | 0.6% |
| FCF Margin | 18.1% | 21.7% | 19.4% | 13.3% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $0.61 | $0.60 | -1.6% | ||
| Q1'26 | $0.85 | $0.57 | -32.9% | ||
| Q4'25 | $0.65 | $0.70 | +7.7% | ||
| Q3'25 | $0.72 | $0.74 | +2.8% | ||
| Q2'25 | $0.57 | $0.62 | +8.8% | ||
| Q1'25 | $0.78 | $0.91 | +16.7% | ||
| Q4'24 | $0.72 | $0.79 | +9.7% | ||
| Q3'24 | $0.73 | $0.89 | +21.9% |
Total return is -7.5% (1Y), lagging the benchmark by -32.5%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -8.7% | -18.0% | — |
| 1Y | -7.5% | -32.5% | — |
| 3YCAGR | -18.3% | -37.4% | — |
| 5YCAGR | -17.8% | -30.3% | — |
| 10YCAGR | -5.3% | -18.8% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Pacira BioSciences, Inc. (PCRX) valuation, health, and returns.
Based on peer relative multiples, Pacira BioSciences, Inc. appears Cheap versus peers compared to industry peers.
Pacira BioSciences, Inc. has multiple valuation anchors: Peer Relative Fair Value: $29.92 | Wall Street Analyst Target: $32.00 (implying +43.3% upside). A convergence of these signals offers higher conviction.
Pacira BioSciences, Inc. displays fair financial health with a composite quality score of 52/100, supported by a Altman Z-Score of 1.3 (distress zone), Piotroski F-Score of 9/9, Return on Invested Capital (ROIC) of 2.3%.
Pacira BioSciences, Inc. returns capital via buybacks instead of dividends, carrying a 16.9% buyback yield and reducing outstanding shares by -2.6% in the last 12 months.
Pacira BioSciences, Inc.'s current growth trajectory is Stable. The company achieved +3.6% 1Y revenue growth and +107.4% 1Y EPS growth, compared to its 3Y revenue CAGR of +2.9%.
Wall Street consensus is Hold based on 36 analysts, beating EPS expectations in 50% of recent quarters with a -2-quarter streak. The consensus price target represents a +43.3% change from current levels.
Investment risks for Pacira BioSciences, Inc. include: -29.6% 1-year max drawdown, elevated distress risk. Volatility risk is characterized by a beta of 0.43x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.